4-(6,7-dimethoxy-4-oxo-2H-1,3-benzoxazin-3-yl)butyl methanesulfonate | 148341-71-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 4-(6,7-dimethoxy-4-oxo-2H-1,3-benzoxazin-3-yl)butyl methanesulfonate
• CAS: 148341-71-3
• 化学式: C₁₅H₂₁NO₇S
• 分子量: 359.4
• InChiKey: PHAOTMHJKIWZTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  99.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(6,7-dimethoxy-4-oxo-2H-1,3-benzoxazin-3-yl)butyl methanesulfonate 在 甲酸 作用下， 反应 0.92h， 生成 3-[4-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]butyl]-6,7-dimethoxy-2H-1,3-benzoxazin-4-one
  参考文献：
  名称：

  Synthesis and bradycardic activity of a series of substituted 3-aminoalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones as potent antiischemics

  摘要：

  A series of 2,3-dihydro-4H-1,3-benzoxazin-4-ones substituted at the 3-position with an arylalkyaminoalkyl group have been synthesized and their specific bradycardic and antiarrythmic activities evaluated. Bradycardia is optimal when the aromatic rings are substituted with methoxy groups and the side-chain amine is N-methylated. N-Demethylated and 2-alkylated derivatives show the highest antiarrhythmic activity but have little bradycardid action. Most of the compounds described are more potent than Falipamil. Compound lm (F 3226) has been selected for further pharmacological tests and the bradycardic activity has been confirmed when administered orally to anesthetized rats without notable side effects.

  DOI：

  10.1016/0223-5234(93)90027-c
• 作为产物：
  描述：

  甲基磺酰氯 、 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.08h， 生成 4-(6,7-dimethoxy-4-oxo-2H-1,3-benzoxazin-3-yl)butyl methanesulfonate
  参考文献：
  名称：

  Synthesis and bradycardic activity of a series of substituted 3-aminoalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones as potent antiischemics

  摘要：

  A series of 2,3-dihydro-4H-1,3-benzoxazin-4-ones substituted at the 3-position with an arylalkyaminoalkyl group have been synthesized and their specific bradycardic and antiarrythmic activities evaluated. Bradycardia is optimal when the aromatic rings are substituted with methoxy groups and the side-chain amine is N-methylated. N-Demethylated and 2-alkylated derivatives show the highest antiarrhythmic activity but have little bradycardid action. Most of the compounds described are more potent than Falipamil. Compound lm (F 3226) has been selected for further pharmacological tests and the bradycardic activity has been confirmed when administered orally to anesthetized rats without notable side effects.

  DOI：

  10.1016/0223-5234(93)90027-c

文献信息

• US5308844A
  申请人：——

  公开号：US5308844A

  公开（公告）日：1994-05-03